Cisplatin/Gemcytobine (CG) vs Cisplatin/Gemcytobine/Vinorelbine (CGV) vs Sequential Doublets of Gemcytobine/Vinorelbine Followed by Ifosfamide/Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase

James Metz, MD

University of Pennsylvania Cancer
Last Modified: May 12, 2001

Presenter: V. Alberola
Affiliation: Spanish Lung Cancer Group


    The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens, including a regimen without Cisplatin based therapy.

Materials and Methods:

  • This study included patients with stage IIIb and IV NSCLC.
  • Most patients were has ECOG performance status 0 or 1.
  • Patients were randomized to receive CG (n=166) vs CGV (n=176) vs GV/IV (n=175)


  • anemia and nausea/vomiting were significantly increased in the CGV regimen
  • The median survival, 1 year survival, and time to progression were not significantly different between the arms

Authors' Conclusions

  • The response rate, time to progression, and survival were the same for CG as the addition of a 3rd agent
  • The hematologic toxicity was increased in the Cisplatin containing arms
  • There was no survival differences between the regimens

Clinical/Scientific Implications:

  • The addition of a third agent to a Cisplatin containing regimen was not shown to increase the benefits for patients
  • The experimental arms in this study were not superior to the control are of CG

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen


Catherine and Finn
by OncoLink Editorial Team
December 01, 2015